Form 8-K - Current report:
SEC Accession No. 0001193125-26-110681
Filing Date
2026-03-17
Accepted
2026-03-17 16:02:02
Documents
10
Period of Report
2026-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K antx-20260317.htm   iXBRL 8-K 46583
2 EX-99.1 antx-ex99_1.htm EX-99.1 201580
  Complete submission text file 0001193125-26-110681.txt   372214

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT antx-20260317.xsd EX-101.SCH 26029
13 EXTRACTED XBRL INSTANCE DOCUMENT antx-20260317_htm.xml XML 4921
Mailing Address 1300 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025
Business Address 1300 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 26761655
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)